vTv Therapeutics Inc. (NASDAQ:VTVT) Receives $53.00 Average Target Price from Analysts

Shares of vTv Therapeutics Inc. (NASDAQ:VTVT) have been assigned a consensus recommendation of “Moderate Buy” from the six ratings firms that are currently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating and five have issued a buy rating on the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $53.00.

VTVT has been the topic of several recent analyst reports. BTIG Research reissued a “buy” rating and set a $49.00 target price on shares of vTv Therapeutics in a research note on Wednesday, March 11th. Wall Street Zen upgraded vTv Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, March 14th. Evercore assumed coverage on vTv Therapeutics in a research report on Thursday, March 12th. They set an “outperform” rating and a $44.00 price target on the stock. HC Wainwright restated a “buy” rating and set a $47.00 price objective (up from $36.00) on shares of vTv Therapeutics in a research report on Friday, December 19th. Finally, TD Cowen initiated coverage on vTv Therapeutics in a report on Monday, January 5th. They issued a “buy” rating on the stock.

vTv Therapeutics Price Performance

vTv Therapeutics stock opened at $38.12 on Wednesday. The firm’s 50 day simple moving average is $36.82 and its 200-day simple moving average is $32.57. The company has a market cap of $150.19 million, a P/E ratio of -11.38 and a beta of 0.40. vTv Therapeutics has a fifty-two week low of $14.00 and a fifty-two week high of $44.00.

vTv Therapeutics (NASDAQ:VTVT) last issued its quarterly earnings results on Tuesday, March 10th. The biotechnology company reported ($0.58) EPS for the quarter, beating the consensus estimate of ($1.09) by $0.51.

Institutional Investors Weigh In On vTv Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. 683 Capital Management LLC purchased a new position in shares of vTv Therapeutics during the 4th quarter valued at $731,000. Goldman Sachs Group Inc. acquired a new stake in vTv Therapeutics during the fourth quarter valued at $221,000. Geode Capital Management LLC grew its stake in vTv Therapeutics by 84.3% in the fourth quarter. Geode Capital Management LLC now owns 28,194 shares of the biotechnology company’s stock valued at $1,128,000 after purchasing an additional 12,896 shares in the last quarter. Finally, Baker BROS. Advisors LP increased its position in vTv Therapeutics by 52.4% in the 3rd quarter. Baker BROS. Advisors LP now owns 148,314 shares of the biotechnology company’s stock worth $3,463,000 after purchasing an additional 51,000 shares during the last quarter. Hedge funds and other institutional investors own 17.51% of the company’s stock.

vTv Therapeutics Company Profile

vTv Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Westport, Connecticut, focused on discovering and developing orally administered small-molecule therapies for chronic diseases. Employing its proprietary medicinal chemistry platform, the company seeks to generate novel compounds that modulate key disease pathways while optimizing safety and pharmacokinetic properties.

The company’s lead candidate, azeliragon (TTP488), is an oral inhibitor of the receptor for advanced glycation end products (RAGE) and has completed Phase II/III clinical evaluation in early-stage Alzheimer’s disease.